<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00149734</url>
  </required_header>
  <id_info>
    <org_study_id>04-0255</org_study_id>
    <secondary_id>R01MH050787</secondary_id>
    <secondary_id>COMIRB # 04-0255</secondary_id>
    <secondary_id>DNBBS 73-MCR</secondary_id>
    <nct_id>NCT00149734</nct_id>
  </id_info>
  <brief_title>Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia</brief_title>
  <official_title>Atypical Antipsychotics and P50 Sensory Gating</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effects of ondansetron on auditory nerve activity in people with
      schizophrenia who are being treated with new antipsychotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a devastating brain disorder. Most people with schizophrenia have difficulty
      filtering out unimportant auditory information. They have an inability to appropriately
      inhibit, or gate, sensory information that enters the ear. Standard treatments do not address
      this problem. When the drug ondansetron is taken in addition to typical antipsychotic drugs,
      P50 auditory gating improves. However, ondansetron has not been used with some of the newer,
      atypical antipsychotic drugs. This study will evaluate the effect of combining ondansetron
      with newer, atypical antipsychotic drugs on P50 auditory gating.

      Participants in this double-blind study will be randomly assigned to receive either
      ondansetron or placebo for 3 months. Upon completion of the first 3 months, participants will
      be crossed over to receive the other treatment for an additional 3 months. All participants
      will also take an atypical antipsychotic drug, including olanzapine, quetiapine, or
      aripiprazole. Auditory gating will be assessed using computerized cognitive testing and
      functional magnetic resonance imaging (fMRI) at baseline and Months 3 and 6. Vital signs and
      evoked potentials will be assessed at Weeks 1, 3, and 6. Clinical symptoms and cognitive
      abilities will also be evaluated to determine the effectiveness of ondansetron.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>P50 sensory gating</measure>
    <time_frame>Measured at Months 3 and 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive testing</measure>
    <time_frame>Measured at Months 3 and 6</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Ondansetron followed by placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take ondansetron then placebo plus an atypical antipsychotic drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by Ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take placebo then ondansetron plus an atypical antipsychotic drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron followed by placebo</intervention_name>
    <description>Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.</description>
    <arm_group_label>Ondansetron followed by placebo</arm_group_label>
    <other_name>Zofran, Zuplenz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo followed by Ondansetron</intervention_name>
    <description>Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.</description>
    <arm_group_label>Placebo followed by Ondansetron</arm_group_label>
    <other_name>Zofran, Zuplenz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for schizophrenia

          -  Stable, chronic schizophrenia

          -  Currently taking atypical medications

          -  Use of effective form of contraception throughout study

        Exclusion Criteria:

          -  History of any alcohol or drug abuse within 3 months of study start date

          -  Any other major neurological disorders

          -  History of or current head trauma

          -  Any medical conditions affecting the central nervous system

          -  Current epilepsy, asthma, migraine headache, previous myocardial infarction, stroke,
             diabetes, hypertension, narrow angle glaucoma, or neuromuscular illnesses

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence E. Adler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Health Sciences Center, VISN19 MIRECC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Denver VAMC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adler LE, Cawthra EM, Donovan KA, Harris JG, Nagamoto HT, Olincy A, Waldo MC. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry. 2005 Feb;162(2):386-8.</citation>
    <PMID>15677607</PMID>
  </reference>
  <reference>
    <citation>Adler LE, Olincy A, Cawthra EM, McRae KA, Harris JG, Nagamoto HT, Waldo MC, Hall MH, Bowles A, Woodward L, Ross RG, Freedman R. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry. 2004 Oct;161(10):1822-8.</citation>
    <PMID>15465979</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Ondansetron</keyword>
  <keyword>P50 sensory gating</keyword>
  <keyword>Evoked potentials</keyword>
  <keyword>5-HT3 receptors</keyword>
  <keyword>Atypical antipsychotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

